On March 9, 2022 Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, reported that a poster featuring preclinical candidate BBT-207 will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 annual meeting taking place on April 8-13 in New Orleans, Louisiana (Press release, Bridge Biotherapeutics, MAR 9, 2022, View Source [SID1234609828]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The following abstract is now available on AACR (Free AACR Whitepaper)’s website.
Presentation Title: BBT-207, a Novel, 4th Generation, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) With Broad-Spectrum Activity to Both Treatment-Emergent and Drug-Naive Mutants for the Treatment of NSCLC
Session Category: Experimental and Molecular Therapeutics
Session Title: Tyrosine Kinase and Phosphatase Inhibitors (PO.ET06.01)
Session Date & Time: Tuesday, April 12, 2022, 1:30 pm — 5:00 pm
Abstract Number: 3346
BBT-207, which is currently under IND-enabling preclinical development, is an internally discovered fourth generation EGFR TKI (Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor) with potent preclinical activity against a broad range of EGFR mutations in non-small cell lung cancer (NSCLC). Preclinical activity profile of BBT-207 allows it to be positioned in earlier line settings for the first, second and third generation EGFR TKI resistant patients.
BBT-207 was developed with the goal of providing treatment options in earlier line settings such as for patients who harbor C797S double mutations that arise from the progression on the third generation EGFR TKIs in NSCLC.
"We are excited to showcase the preclinical data which suggests that BBT-207 may have the potential to be positioned as a frontline treatment as targeting C797S mutations in NSCLC, especially C797S double mutations," and "we will continue to make advancements of BBT-207 and anticipate submitting the US IND by the end of this year," said Jimmy Jin M.D., Ph.D., the Head of Discovery Biology of Bridge Biotherapeutics.
BBT-207 is planned to enter a Phase I study in metastatic NSCLC in 1H 2023.